Clinical Trials Logo

Bone Neoplasms clinical trials

View clinical trials related to Bone Neoplasms.

Filter by:

NCT ID: NCT00960063 Terminated - Neoplasms Clinical Trials

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Start date: November 11, 2009
Phase: Phase 1
Study type: Interventional

This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in conformance with Good Clinical Practices. This study will evaluate the safety, tolerability and dose-finding of robatumumab when administered in combination with temozolomide and irinotecan (Arm A); or cyclophosphamide, doxorubicin, and vincristine (Arm B), or ifosfamide and etoposide (Arm C). The primary study hypothesis is that robatumumab can be safely administered in combination with chemotherapy regimens in pediatric participants with solid tumors.

NCT ID: NCT00889590 Terminated - Clinical trials for Giant Cell Tumor of Bone

Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

HR-GCT
Start date: December 2008
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomised phase II trial in patients with high risk GCT. Primary objective: - Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high risk' GCT as compared to standard care Secondary objectives: - Determine the relapse free survival - Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT

NCT ID: NCT00757757 Terminated - Prostate Cancer Clinical Trials

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Start date: September 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

NCT ID: NCT00632294 Terminated - Bone Cancer Clinical Trials

Retrospective Study of the Biomechanical Properties of Large Allografts

Start date: December 2007
Phase: N/A
Study type: Observational

Primary Objectives: 1. To evaluate the material properties, histomorphometric indices, bone mineral density (BMD), and presence of microfractures in retrieved large allograft cortical bone specimens removed from orthopaedic oncology patients. 2. To correlate physical properties to patient demographics and medical treatment received.

NCT ID: NCT00381095 Terminated - Cancer Clinical Trials

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

COPE
Start date: December 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the analgesic efficacy of flexibly-dosed pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain.

NCT ID: NCT00099203 Terminated - Pain Clinical Trials

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 and then every 3-4 weeks) or zoledronic acid (4mg iv on day 1 and then every 3-4 weeks). The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00099177 Terminated - Pain Clinical Trials

A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

Start date: August 2005
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare the efficacy of a regimen of intravenous (iv) and oral Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 followed by Bondronat 5Omg po daily from day 22 to week 24) or zoledronic acid (4mg iv on day 1, and then every 3-4 weeks). The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.